WO2004002440A1 - Cosmetic composition for the skin containing melanotan ii and the use thereof as a suntan preparation - Google Patents

Cosmetic composition for the skin containing melanotan ii and the use thereof as a suntan preparation Download PDF

Info

Publication number
WO2004002440A1
WO2004002440A1 PCT/EP2003/006772 EP0306772W WO2004002440A1 WO 2004002440 A1 WO2004002440 A1 WO 2004002440A1 EP 0306772 W EP0306772 W EP 0306772W WO 2004002440 A1 WO2004002440 A1 WO 2004002440A1
Authority
WO
WIPO (PCT)
Prior art keywords
characterized
composition according
skin
melanotan ii
composition
Prior art date
Application number
PCT/EP2003/006772
Other languages
German (de)
French (fr)
Inventor
Elfriede Rauch
Original Assignee
Elfriede Rauch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE10228837.2 priority Critical
Priority to DE10228837.2A priority patent/DE10228837B4/en
Application filed by Elfriede Rauch filed Critical Elfriede Rauch
Publication of WO2004002440A1 publication Critical patent/WO2004002440A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/04Preparations for care of the skin for chemically tanning the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes

Abstract

The invention relates to a topically applied cosmetic composition for the skin for use as a suntan preparation. Said composition is characterised by an active content of melanotan II in a cosmetically compatible support.

Description

SKIN COSMETIC COMPOSITION CONTAINING MELANOTAN II AND THEIR USE AS SKIN BREWING DRYING AGENT

The present invention relates to a topically applicable skin cosmetic composition and the use thereof as tanning agents.

The natural color of human skin is due in part melanin. The formation of melanin takes place in the so-called melanocytes, in particular under the influence of sunlight. By the hormones melatonin and Melanotropin (melanocyte-stimulating hormone, MSH) is influenced the agglomeration or dispersion of melanin granules in the melanocytes, and thus the hue of the skin.

Suitable synthetic analogs of the melanocyte-stimulating hormone Melanotan I and Melanotan II are known. Melanotan I is a linear oligopeptide containing all thirteen amino acids of the melanocyte stimulating hormone. Melanotan II is a shortened version of the same cyclic peptide having the amino acid sequence Leu-Asp-His-Phe-Arg-Trp-Lys.

In-vitro and in-vivo experiments with rats have shown that Melanotan II can suppress the food stimulus in cases of over-eating and having a neuropeptidische effect. Furthermore, Melanotan II shows in cell cultures melanocytic interference effect is to stimulate the production of melanin and thus should stimulate the skin tone when used in vivo.

Currently also self-tanning agents are examined on the basis of Melanotan I. To this end, however, an injection of the drug is needed. The increased pigmentation of human skin by subcutaneous injection of Melanotan II is in Dorr et al, Evaluation of Melanotan-II, a potent super cyclic melanotropic peptides in a pilot phase I clinical study. Life Sciences, 1996, Vol. 58, No. 20, page 1777 to 1784 is described. The invention is based, provide the effective and easy to be administered cosmetic skin tanning agent relative to the object.

This object is inventively achieved by a topically applicable skin cosmetic composition comprising an effective amount of Melanotan II, in a cosmetically acceptable carrier. The side effects seen with oral or intravenous administration of Melanotan II can be safely avoided by topical administration. It has surprisingly been found that an application of the Melanotans II even at low concentrations of active ingredients to the skin leads to a sustained skin tanning. Topical administration also allows for the formulation of a variety of preparations, with which the skin condition can be favorably influenced if necessary additional active ingredients.

Preferably, the composition contains between 0.1 and 0.3 wt.% Melanotan II. An active substance content below 0.1% requires a longer period of use in order to achieve a visible browning. Shares above 0.3% increase the impact is no longer essential. The Melanotan II is particularly preferably in liposomatischer solution. For the preparation liposomatischer solutions one or more phospholipids can be used in a known manner. Particularly preferred is the use of phosphatidylcholine. The use liposomatischer solutions enhances the natural appearance of the skin.

If the cosmetic composition of the invention used as a skin tanning agents, they may be in the commonly used for this type forms. In particular, the cosmetically acceptable carrier may be an oily or oily-alcoholic lotion, an emulsion of the type water-in-oil or oil-in-water, as a cream or a milk, in the form of oily-alcoholic, oily-aqueous or aqueous-alcoholic gels, as a pin be conditioned or as an aerosol.

The composition may be also formulated as a day cream, night cream, face cream, facial or body lotion, foam cream or foam mask, hand cream, cleansing cream or lotion, cleansing cream, face lotion, or facial mask, lip balm, skin protectants, sunscreen cosmetics, bath preparation, or body oil.

Further, the composition may comprise cosmetic adjuvants which are customary for cosmetic compositions, such as solvents, thickeners, emollients, humectants, surfactants, preservatives, antifoams, perfumes, oils, waxes, lanolin, allantoin, propellants, dyes and / or pigments, UV filters to protect against UV-A and / or UV-B rays and other Inkredenzien commonly used in cosmetics, as well as water.

As dissolving agent, an oil, wax or other fats, a lower monoalcohol or lower polyol or mixtures thereof may, in particular water, can be used. Particularly preferred monoalcohols or polyols include ethanol, isopropanol, propylene glycol, glycerin and sorbitol.

If the composition is in the form of an emulsion such as a cream or milk, it particularly preferably comprises fatty alcohols, fatty acids, fatty acid ester, in particular triglycerides of fatty acids, lanolin, natural or synthetic oils or waxes and emulsifiers in presence of water.

If a use of the composition according to the invention is desired as an oily lotion, the composition of natural or synthetic oils and waxes, lanolin and / or fatty acid ester, in particular triglycerides of fatty acids comprises. When used as an oily-alcoholic lotion, the composition comprises a lower alcohol such as ethanol, a glycol such as propylene glycol and / or a polyol such as glycerol, and oils, waxes and fatty acid ester, in particular triglycerides of fatty acids.

Further, The inventive composition also be present as an alcoholic gel which comprises one or more lower alcohols or polyols such as ethanol, propylene glycol or glycerol, and a thickener such as silica. The oily-alcoholic gels also comprise natural or synthetic oil or wax. Finally, the inventive composition may be packaged as a fixed pin, and natural or synthetic waxes and oils, fatty alcohols, fatty acid ester, lanolin and other fats.

Suitable UV filters are, for example derivatives of cinnamic acid, benzylidenecamphor and derivatives thereof, p-aminobenzoic acid and its derivatives, salicylic acid derivatives, benzophenone derivatives and dibenzoylmethane derivatives.

When conditioning the inventive composition as an aerosol, the customary propellants, such as alkanes, fluoroalkanes and chlorofluoroalkanes are used.

Suitable thickeners or gelling agents are, for example Goagummi, heterobiopolysaccharides, xanthan gum, scleroglucans, cellulose derivatives such as methyl cellulose, hydroxyethyl cellulose, hydroxymethylpropyl cellulose, alkali metal salts of carboxymethyl cellulose, and polyacrylic acids.

Finally, the composition may also contain other active ingredients for the treatment or prevention of skin diseases or skin conditioning, provided these drugs do not affect the effect of Melanotan II.

Other features and advantages of the present invention will become apparent from the following description of preferred embodiments which should be understood, however, merely as an example and not in a limiting sense.

Example 1:

cosmetic composition

It was contained in liposomatischer solution cosmetic composition prepared with the following ingredients a Melanotan II, the proportions of the ingredients are given in percent by weight:

Figure imgf000005_0001
Figure imgf000006_0001

Cosmetic experiment

The composition thus prepared was used to treat five female volunteers aged between 25 and 40 years. The application was made by daily application of the composition on the right forearm. The volunteers were asked to lead a normal life, but suspend the right and left forearms to sunlight and avoid wearing clothes with long sleeves. The experiment was conducted in the spring under favorable climatic conditions and therefore good tanning.

The results of the reaction melanogenetischen were very satisfactory; a beginning, very pronounced browning of the skin of the treated forearm showed on the third day of the application, while the untreated left forearm remained normal. Towards the end of the experiment, which was conducted over a period of two weeks was shown in comparison to the non-treated body regions of higher browning value. The pronounced melanogenetische stimulation by use of Melanotan II is detected thereby.

The determined in the experiments optimum content of Melanotan is between 0.1 wt.% And 0.3 wt.%. The composition can be formulated as conventional cosmetic emulsion or a mask preparation preferable. This puts an effective tanning agent is in a single dosage form. Example 2:

To prepare a lip balms the following ingredients are combined, the proportions of the ingredients are given in percent by weight:

Figure imgf000007_0001

The composition is stable and shows a skin-tanning effect.

Example 3:

To prepare a body lotion, the following ingredients were combined, the proportions of the ingredients are given in percent by weight:

Figure imgf000007_0002

Figure imgf000008_0001

The composition is stable and shows a skin-tanning effect.

Claims

claims
1. A topically applicable skin cosmetic composition for use as a skin tanning composition, characterized by an effective content of Melanotan II, in a cosmetically acceptable carrier.
2. Composition according to claim 1, characterized in that the composition contains between 0.1 and 0.3 wt .-% Melanotan II contains.
3. Composition according to any one of claims 1 or 2, characterized in that the Melanotan II is present in liposomatischer solution.
4. A composition according to claim 3, characterized in that the liposomatische solution containing one or more phospholipids.
5. The composition according to claim 4, characterized in that the phospholipid is phosphatidylcholine.
6. A composition according to any one of the preceding claims, characterized in that the cosmetic acceptable excipients as an oily or oily-alcoholic lotion, an emulsion of the type water-in-oil or oil in water, cream or milk, an oily-alcoholic, oily-aqueous or aqueous-alcoholic gels, a pin or an aerosol is conditioned.
7. A composition according to any one of the preceding claims, characterized in that it contains additional pharmaceutically and / or dermatologically acceptable excipients.
8. A method for improving skin tanning, characterized by the application of a skin cosmetic composition according to any of the preceding claims to the skin and applying an effective amount of Melanotan II.
9. Use of Melanotan II for the manufacture of a topically applicable skin cosmetic composition according to any of the preceding claims.
PCT/EP2003/006772 2002-06-27 2003-06-26 Cosmetic composition for the skin containing melanotan ii and the use thereof as a suntan preparation WO2004002440A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE10228837.2 2002-06-27
DE10228837.2A DE10228837B4 (en) 2002-06-27 2002-06-27 Skin cosmetic composition and use of the composition as a skin tanning agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003246597A AU2003246597A1 (en) 2002-06-27 2003-06-26 Cosmetic composition for the skin containing melanotan ii and the use thereof as a suntan preparation

Publications (1)

Publication Number Publication Date
WO2004002440A1 true WO2004002440A1 (en) 2004-01-08

Family

ID=29723498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006772 WO2004002440A1 (en) 2002-06-27 2003-06-26 Cosmetic composition for the skin containing melanotan ii and the use thereof as a suntan preparation

Country Status (3)

Country Link
AU (1) AU2003246597A1 (en)
DE (1) DE10228837B4 (en)
WO (1) WO2004002440A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1812034A1 (en) * 2004-10-08 2007-08-01 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
WO2009124754A1 (en) * 2008-04-08 2009-10-15 Merck Patent Gmbh Compositions containing cyclic peptides and methods of use
WO2014160015A1 (en) * 2013-03-13 2014-10-02 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004623A1 (en) * 1986-02-03 1987-08-13 University Patents, Inc. Method of stimulating melanocytes by topical application of analogs of alpha-msh, and compositions for use in same
EP0386680A1 (en) * 1989-03-07 1990-09-12 Plough, Inc. Liposome compositions
US5641509A (en) * 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
WO2000004873A1 (en) * 1998-07-22 2000-02-03 Smith & Nephew Plc Dermatological compositions for the treatment of scars

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3851002D1 (en) * 1987-05-22 1994-09-15 University Patents Inc Linear and cyclic analogs of alpha-MSH fragments with extraordinary effect.
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
DE19931310A1 (en) * 1999-07-07 2001-01-11 Beiersdorf Ag Cosmetic and dermatological use of phospholipid compounds especially ceramide compounds, for enhancing skin tanning and for stimulation of melanogenesis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004623A1 (en) * 1986-02-03 1987-08-13 University Patents, Inc. Method of stimulating melanocytes by topical application of analogs of alpha-msh, and compositions for use in same
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
EP0386680A1 (en) * 1989-03-07 1990-09-12 Plough, Inc. Liposome compositions
US5641509A (en) * 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
WO2000004873A1 (en) * 1998-07-22 2000-02-03 Smith & Nephew Plc Dermatological compositions for the treatment of scars

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DORR R T ET AL: "EVALUATION OF MELANOTAN-II, A SUPERPOTENT CYCLIC MELANOTROPIC PEPTIDE IN A PILOT PHASE-I CLINICAL STUDY", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 58, no. 20, 1996, pages 1777 - 1784, XP001079873, ISSN: 0024-3205 *
HADLEY M E ET AL: "DISCOVERY AND DEVELOPMENT OF NOVEL MELANOGENIC DRUGS//MELANOTAN-I AND -II", INTEGRATION OF PHARMACEUTICAL DISCOVERY AND DEVELOPMENTS: CASE STUDIES, XX, XX, 1998, pages 575 - 595, XP001064545 *
PAWELEK JOHN M: "Approaches to increasing skin melanin with MSH Analogs and synthetic melanins", PIGMENT CELL RESEARCH, vol. 14, no. 3, 14 January 2001 (2001-01-14), pages 155 - 160, XP002255862 *

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1812034A1 (en) * 2004-10-08 2007-08-01 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
EP1812034A4 (en) * 2004-10-08 2009-07-29 Clinuvel Pharmaceuticals Ltd Compositions and methods for inducing melanogenesis in a subject
EP2368562A1 (en) * 2004-10-08 2011-09-28 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
EP2939686A1 (en) * 2004-10-08 2015-11-04 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
WO2009124754A1 (en) * 2008-04-08 2009-10-15 Merck Patent Gmbh Compositions containing cyclic peptides and methods of use
US20110027209A1 (en) * 2008-04-08 2011-02-03 Merck Patent Gesellschaft Compositions Containing Cyclic Peptides And Methods Of Use
US10278911B2 (en) 2008-04-08 2019-05-07 Merck Patent Gmbh Compositions containing cyclic peptides and methods of use
RU2555357C2 (en) * 2008-04-08 2015-07-10 Мерк Патент Гмбх Compositions, containing cyclic peptides and methods of applying thereof
US9682102B2 (en) 2013-03-13 2017-06-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9439926B2 (en) 2013-03-13 2016-09-13 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9480642B2 (en) 2013-03-13 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9498535B2 (en) 2013-03-13 2016-11-22 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9585817B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9585829B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9636291B2 (en) 2013-03-13 2017-05-02 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9687504B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9694029B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9694083B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9700626B2 (en) 2013-03-13 2017-07-11 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9717680B2 (en) 2013-03-13 2017-08-01 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9757467B2 (en) 2013-03-13 2017-09-12 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9827316B2 (en) 2013-03-13 2017-11-28 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9844506B2 (en) 2013-03-13 2017-12-19 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9872818B2 (en) 2013-03-13 2018-01-23 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9913793B2 (en) 2013-03-13 2018-03-13 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9931370B2 (en) 2013-03-13 2018-04-03 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9937221B2 (en) 2013-03-13 2018-04-10 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9943562B2 (en) 2013-03-13 2018-04-17 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9956290B2 (en) 2013-03-13 2018-05-01 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US10028994B2 (en) 2013-03-13 2018-07-24 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US10034944B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US10034828B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
WO2014160015A1 (en) * 2013-03-13 2014-10-02 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
US10071117B2 (en) 2013-03-13 2018-09-11 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US10080768B2 (en) 2013-03-13 2018-09-25 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10155048B2 (en) 2013-03-13 2018-12-18 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10188603B2 (en) 2013-03-13 2019-01-29 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US10213457B2 (en) 2013-03-13 2019-02-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US10064955B2 (en) 2013-03-13 2018-09-04 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention

Also Published As

Publication number Publication date
DE10228837A1 (en) 2004-01-15
DE10228837B4 (en) 2016-01-07
AU2003246597A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
CA2470201C (en) Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
JP2812690B2 (en) Photoprotective composition containing a tocopherol sorbate
CA2149861C (en) Self-tanning cosmetic compositions and methods of using the same
ES2121178T5 (en) synergistic combinations of the active substance for cosmetic care or dermatological skin or integumentary elements (hair and nails).
US6596761B2 (en) Cosmetic and dermatological preparation with flavonoids
EP1339413B1 (en) Compositions comprising complexes of phosphate derivatives of tocopherol
ES2374226T3 (en) Employment of creatine and / or creatine derivatives in dermatological preparations.
EP1002526B1 (en) Skin whitening composition containing bearberry extract and a reducing agent
US4603046A (en) Improved sunscreen or sunblock composition
EP1203579B1 (en) Cosmetic skin care compositions containing alpha interferon
JP2682967B2 (en) Sunscreen cosmetic compositions and methods of use thereof
US5006331A (en) Compositions and method of strengthening hair
JP2731705B2 (en) Cosmetic composition and dermatological pharmaceutical composition
KR100221112B1 (en) External dermatological composition
AU710889B2 (en) Skin tanning compositions and method
DE19653736C2 (en) Cosmetic preparation with added peptide
ES2255129T3 (en) Monohydric alcohol-free composition for topical use comprising solubilized ethylcellulose.
ES2261446T3 (en) Use of a composition that inhibits hair growth.
US4707354A (en) Mature skin treatment and protectant compositions and methods of using same
ES2231220T3 (en) Topical agents with protective and regenerative effect containing idebenone.
JP3091782B2 (en) Cosmetic slimming composition
AU737402B2 (en) Combination of erythrulose and a reducing sugar with self-tanning properties
US20040122109A1 (en) Preparation for hair and/or scalp
JPH08208505A (en) Topical composition containing substance p antagonist
ES2259034T3 (en) Use of an enantiomer of lipoic acid in cosmetics and dermatology.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP